INT82737

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 1997
Last Reported 2004
Negated 0
Speculated 2
Reported most in Abstract
Documents 7
Total Number 9
Disease Relevance 4.60
Pain Relevance 2.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Hmox2) endoplasmic reticulum (Hmox2) plasma membrane (Hmox2)
Anatomy Link Frequency
skin 2
Hmox2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
COX2 5 100.00 Very High Very High Very High
Etanercept 1 99.36 Very High Very High Very High
cINOD 12 99.26 Very High Very High Very High
Inflammation 16 99.12 Very High Very High Very High
cytokine 1 98.60 Very High Very High Very High
Analgesic 5 96.56 Very High Very High Very High
Arthritis 5 91.92 High High
methotrexate 2 89.60 High High
diclofenac 3 88.96 High High
aspirin 1 86.72 High High
Disease Link Frequency Relevance Heat
Colon Cancer 2 99.92 Very High Very High Very High
Skin Cancer 2 99.80 Very High Very High Very High
Uveitis 1 99.24 Very High Very High Very High
INFLAMMATION 25 99.14 Very High Very High Very High
Cancer 2 98.56 Very High Very High Very High
Injury 6 98.28 Very High Very High Very High
Necrosis 1 98.28 Very High Very High Very High
Keratosis 8 95.32 Very High Very High Very High
Disease 3 95.24 Very High Very High Very High
Arthritis 6 91.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effect of the selective cyclo-oxygenase-type-2 (COX-2) inhibitor etodolac on gastric mucosal integrity and gastric acid secretion was investigated in the rat.
Spec (investigated) Regulation (effect) of cyclo-oxygenase-type-2
1) Confidence 0.14 Published 2001 Journal J. Physiol. Paris Section Abstract Doc Link 11595417 Disease Relevance 0.19 Pain Relevance 0.04
Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity.
Regulation (Effects) of cyclo-oxygenase 2 in skin associated with injury and cox2
2) Confidence 0.08 Published 2004 Journal Br J Surg Section Title Doc Link 15505871 Disease Relevance 0.10 Pain Relevance 0.14
It exists in at least two isoforms: the constitutive (cyclo-oxygenase-1) and the inducible (cyclo-oxygenase-2) which is controlled by a number of factors, including cytokines and intracellular messengers.
Regulation (controlled) of cyclo-oxygenase-2 associated with cytokine
3) Confidence 0.06 Published 2001 Journal Dig Liver Dis Section Abstract Doc Link 11827358 Disease Relevance 0.16 Pain Relevance 0.22
At this time the introduction of the cyclo-oxygenase 2 inhibitors and etanercept (soluble tumour necrosis factoralpha.p75 fusion protein) may herald an era of more specific and effective therapy.
Regulation (introduction) of cyclo-oxygenase 2 associated with necrosis, cancer and etanercept
4) Confidence 0.05 Published 1999 Journal Drugs Section Abstract Doc Link 10595864 Disease Relevance 0.86 Pain Relevance 0.37
Its primary anti-inflammatory mechanism of action is through a selective effect on cyclo-oxygenase-2 (COX-2).
Regulation (effect) of cyclo-oxygenase-2 associated with inflammation
5) Confidence 0.04 Published 1997 Journal Inflammopharmacology Section Abstract Doc Link 17694363 Disease Relevance 0.80 Pain Relevance 0.66
The recent discovery that cyclo-oxygenase-2 (COX-2) is a potential pharmacological target for skin tumours has prompted interest in using topical nonsteroidal anti-inflammatory drugs (NSAIDs) as a treatment for AKs.
Regulation (target) of cyclo-oxygenase-2 in skin associated with inflammation, cinod, skin cancer and keratosis
6) Confidence 0.01 Published 2003 Journal J Cosmet Dermatol Section Abstract Doc Link 17163919 Disease Relevance 1.01 Pain Relevance 0.46
OBJECTIVE: To examine the role of selective cyclo-oxygenase-2 (COX-2) inhibitors in the anti-inflammatory armamentarium.
Spec (examine) Regulation (role) of cyclo-oxygenase-2
7) Confidence 0.00 Published 2000 Journal Aust Fam Physician Section Body Doc Link 11008387 Disease Relevance 0 Pain Relevance 0
Regular administration of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the incidence of colorectal cancer by targeting cyclo-oxygenase-2 (Cox-2), a key enzyme in arachidonic acid metabolism.
Regulation (targeting) of cyclo-oxygenase-2 associated with inflammation, colon cancer and cinod
8) Confidence 0.00 Published 1999 Journal J. Pathol. Section Abstract Doc Link 10398082 Disease Relevance 0.87 Pain Relevance 0.20
A new generation of non-steroidal anti-inflammatory drugs has been described that selectively targets the inducible isoform of cyclo-oxygenase, cyclo-oxygenase 2 (COX-2).
Regulation (targets) of cyclo-oxygenase 2 associated with inflammation and cinod
9) Confidence 0.00 Published 2000 Journal Lancet Section Abstract Doc Link 10696997 Disease Relevance 0.62 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox